CHI3L1 has been studied as a biomarker candidate for the early screening of neuritis and examination of AD [128] and is high in the serum of patients with AD [129] and the CFS of patients with MS [130]. Here, CHI3L1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.